hue of the digits. Livedo reticularis is manifested by a reddish-blue mottling of the skin in a net-like pattern. Both conditions are thought to be due to vasospasm in the microvasculature leading to a reduction in blood flow and desaturation of oxyhemoglobin.
Raynaud's phenomenon in the absence of other disorders is called primary Raynaud's phenomenon, or Raynaud's disease. It is important to make the distinction between this and the secondary forms of Raynaud's phenomenon. Secondary Raynaud's phenomenon can be associated with an underlying autoimmune, inflammatory, hematopoietic disease or a connective tissue disease such as scleroderma, which is almost invariably accompanied by vasospastic attacks. Secondary Raynaud's phenomenon is commonly associated with significant morbidity, including digital gangrene, and may be life-threatening. The vasospastic attacks are probably due to normal fluctuations in vessel tone that are superimposed upon structural changes in the vessel wall such as myointimal hyperplasia, atheroma, organized thrombus, or extravascular compression. 2 These structural changes may also be associated with an impairment of endothelial function that contributes to abnormal vascular reactivity. 3 By contrast, primary Raynaud's disease has a benign course. Rarely, Raynaud's disease may cause small superficial ulcerations of the tips of the digits, but never gangrene. Raynaud's disease is not associated with systemic disorders, although it may occasionally be associated with other vasospastic disorders, including coronary vasospasm and migraine headaches. 4, 5 Histological examination of digital arteries from patients with Raynaud's disease generally reveals no structural abnormalities. 6 However, minor changes in the microvasculature (i.e. nailfold capillary dimensions) have been reported. 7 These changes are certainly not as pronounced as in those patients with scleroderma and secondary Raynaud's phenomenon. Rather, Raynaud's disease can be considered as a functional disorder of excessive vasoconstriction.
Estimates of the prevalence of Raynaud's disease in the general population vary considerably. However, large epidemiological studies indicate the prevalence is higher in women. 8 Further, the onset of Raynaud's disease generally occurs between menarche and menopause and the severity of the disease is greater over this period. 9 These observations suggest that ovarian steroid hormones may facilitate the factors that underlie the disorder. It is also clear that there is an increased prevalence of Raynaud's disease in family members of affected individuals, 5,10 consistent with a genetic susceptibility to the disorder. These particular issues, together with the major factors that have been implicated in Raynaud's disease, are discussed below.
Adrenergic disturbances in Raynaud's disease

Role of the adrenergic nerves
Neurones of the medulla have axons that descend to activate sympathetic preganglionic neurons in the spinal cord, which in turn send impulses to neurons in the sympathetic ganglia. Nerves derived from the sympathetic ganglia travel with the conduit blood vessels to supply nerve fibers which course through the adventitia and media of the arteries, veins and lymphatic vessels. Localized swellings or varicosities along the length of the nerve fibers form neuroeffector junctions with the vascular smooth muscle. At these neuroeffector junctions, norepinephrine is released by depolarization of the nerve fiber. Norepinephrine stimulates postjunctional alpha adrenoreceptors on the vascular smooth muscle to cause vasoconstriction. In this way, the sympathetic nervous system exerts significant control over vascular tone, vascular resistance and blood flow in the skin, as in other tissues.
Raynaud proposed that the vasospastic attacks of his eponymous phenomenon are triggered by hyperactivity of the sympathetic noradrenergic nerves to the skin. This hypothesis was based on the clinical observation that attacks are often precipitated by ambient cold or mental stress, conditions which are also associated with increased noradrenergic nerve activity to the skin. Consistent with his hypothesis, surgical sympathectomy alleviated the symptoms of patients with Raynaud's disease. 11 Furthermore, heating, which inhibits sympathetic nerve activity to cutaneous vessels, partially reverses the impairment of nutritional flow to the skin in these individuals. 12 Sexual differences in cutaneous blood flow As indicated above, Raynaud's disease is much more common in women than in men. 13 Thus, it is significant that experimental observations indicate a tonic increase in adrenergic activation of cutaneous blood vessels in women relative to men. 14 Basal cutaneous blood flow in the hands and fingers of young women is approximately half that of young men, after accounting for differences in tissue mass. 14 This has been confirmed by using fluid plethysmography, strain gauge plethysmography, and laser Doppler spectroscopy. The difference between the sexes is not due to structural differences in the cutaneous vessels. Indeed, when cutaneous sympathetic activity was inhibited by heating, hand blood flow in women actually exceeded that of men. 14 These observations therefore suggest that the sex difference is due to increased sympathetically induced tone of the cutaneous circulation in women. This appears to be a tonic, rather than cyclical increase in sympathetic influence, as demonstrated by the stability of cutaneous blood flow recordings throughout the menstrual cycle. 14 This increase in sympathetic tone of the cutaneous vessels may reflect a tonic effect of female ovarian hormones as finger blood flow increases after the menopause. 15 Indeed, it has been suggested that the 'hot flashes' that are associated with the menopause may represent intermittent release of increased sympathetically induced tone, as the hormonal influence diminishes. 16 These observations are consistent with the fact that the symptoms of Raynaud's disease often improve after menopause. 17 Whether the increase in sympathetically induced cutaneous vasoconstrictor tone that occurs in women reflects an increase in sympathetic nerve activity to the skin, an increased release of norepinephrine, reduced norepinephrine re-uptake by the nerve varicosities, and/or an increase in the action of norepinephrine on the cutaneous vessels has not been established. However, it has been shown that the vasoconstrictor response evoked in the digits of normal women by an ␣ 1 adrenoceptor agonist was enhanced in the luteal phase of the menstrual cycle when estrogen is relatively high, compared with the follicular phase when plasma estrogen is low. By contrast, digital vasoconstriction evoked by an ␣ 2 adrenoceptor agonist was reduced in the luteal phase compared with the follicular phase. 18 The former finding accords with reports that contraction evoked in rat aorta by the ␣ 1 adrenoceptor agonist phenylephrine was depressed in aortae taken from ovariectomized female rats relative to intact female rats, 19 and that treatment of ovariectomized female rabbits and rats with estrogen enhanced contractile responses of the aorta to norepinephrine and to phenylephrine. 20, 21 This facilitatory effect of estrogen seems to be endothelium-dependent and is discussed further below.
On the basis of these findings it seems likely that the greater sympathetic vasoconstrictor tone observed in the cutaneous circulation of women relative to men reflects, at least in part, an action of estrogen on responses evoked by post-synaptic ␣ 1 adrenoceptors. It might therefore be expected that reflex vasoconstrictor responses mediated by ␣ 1 adrenoceptors would be similarly enhanced by estrogen.
The 'local fault'
Evidence of local modulation of noradrenergic influences by estrogen is of particular interest because the hypothesis that the sympathetic nervous system plays an essential role in Raynaud's disease was questioned by Lewis. He first reported that vasospastic attacks can still occur in Raynaud's patients after local anesthesia of the digital sympathetic nerves, or after sympathectomy. 22, 23 Lewis proposed that there must be a 'local fault' of the digital arteries in Raynaud's disease. He concluded that a functional abnormality is responsible, such that normal vasoconstriction is enhanced by a local factor.
Given that the response to cold, which involves an increase in sympathetic outflow to the digital arteries, is a major precipitant of attacks of vasospasm in Raynaud's disease, it was a key finding that the adrenergic response of human digital arteries is modulated by cooling. Indeed, the response to cooling may represent a 'local fault'. In an in vitro study of human digital arteries obtained at the time of surgery for trauma or tumor, the arteries contracted in response to exogenous norepinephrine, or to electrical stimulation, which releases endogenous norepinephrine from adrenergic nerve endings in the vessel wall ( Figure 1 ). Under both conditions, cooling the arteries caused further contraction. Subsequent studies indicated that the subtype and distribution of postjunctional adrenergic receptors may contribute to this local modulatory effect of cooling.
The distinctive distribution of adrenergic receptors
Classically, postjunctional adrenergic receptors on vascular smooth muscle are of the ␣ 1 subtype and, when stimulated, evoke vasoconstriction. By contrast, adrenergic receptors of the ␣ 2 subtype are prejunctional in location, and when these receptors are stimulated they reduce norepinephrine release from the adrenergic nerve varicosity. However, in some vessels, ␣ 2 adrenoceptors are found in a postjunctional location, on the vascular smooth muscle. When stimulated, these ␣ 2 adrenoceptors also induce vasoconstriction. Importantly, studies performed in vivo on the cutaneous vessels of human digits indicate that the postjunctional receptors are of the ␣ 1 and ␣ 2 receptor subtypes. 24, 25 This was confirmed in digital and limb arteries, excised from limbs surgically removed for trauma or tumor. In more proximal limb vessels (e.g. the radial artery), vasoconstriction to norepinephrine was largely mediated by postjunctional ␣ 1 adrenoceptors. 26 However, in the digital arteries, both postjunctional ␣ 1 and ␣ 2 adrenoceptors played a role. Thus, ␣ 2 adrenoceptors are clustered in the more thermosensitive region of the upper extremities-the digits. This raised the possibility that spatial distribution of the postjunctional adrenergic receptors has functional and clinical implications.
To study the role of the ␣ 1 and ␣ 2 adrenoceptors in regulating finger blood flow under basal conditions in normal subjects and in those individuals with Raynaud's disease, finger blood flow was measured by plethysmography during intra-arterial infusions of saline or adrenergic antagonists. 27 Intra-arterial infusion of the ␣ 1 antagonist prazosin caused a much greater increase in finger blood flow in normal subjects than did the ␣ 2 antagonist yohimbine. By contrast, in those individuals with Raynaud's disease, yohimbine was equally effective as prazosin as a vasodilator. Thus, under resting conditions in normal subjects, ␣ 1 adrenoceptors predominantly regulate finger blood flow whereas, in patients with Raynaud's disease, postjunctional ␣ 2 adrenoceptors play a substantial role as well. 28 Intriguingly, the ␣ 2 adrenoreceptor has an unusual response to changes in temperature as described below.
The temperature paradox: the role of ␣ ␣ 2 adrenoceptors
It is something of a paradox that cold-induced vasoconstriction occurs at all, in that cooling would be expected to slow and attenuate critical processes involved in vascular smooth muscle activation. Extracellular calcium entry and intracellular calcium release, as well as actomyosin ATPase and glycolytic activity are all inhibited by cooling. 28, 29 Furthermore, neuronal release of norepinephrine is reduced by cooling. 30 Therefore, it might be anticipated that cooling would cause vasodilation. Indeed, the phenomenon of cold vasodilation in response to severe cold has been recognized in the digital vasculature of normal subjects for many years. 22, 31 Moreover, cooling relaxes the vasoconstriction induced by prostaglandin F1␣, or depolarizing concentrations of potassium. 28 However, when isolated cutaneous vessels are contracted by exogenous or endogenous norepinephrine, then cooling augments the contraction. 32, 33 Cooke and colleagues proposed that the paradoxical adrenergic response to temperature changes may be related to the postjunctional ␣ 2 adrenoceptors. 28, 34 This was confirmed in subsequent studies. The effect of cold to augment adrenergic vasoconstriction was blocked by ␣ 2 but not ␣ 1 adrenoceptor antagonists. 35, 36 Furthermore, when the isolated vessel was contracted by an ␣ 1 adrenoceptor agonist, cooling caused relaxation, whereas the contraction evoked by an ␣ 2 adrenoceptor agonist was augmented by cooling. These findings are consistent with those of Ekenvall and colleagues who iontophoretically applied ␣ 1 or ␣ 2 adrenoceptor agonists or antagonists to the fingers of normal male subjects and evaluated local finger blood flow by the laser Doppler technique. Activation of ␣ 1 or ␣ 2 adrenoceptors caused vasoconstriction, but local cooling of the finger enhanced only the vasoconstriction to the ␣ 2 agonist. 37 Similar results were obtained by Freedman and coworkers. 38 More recently, in vitro myograph studies of murine tail arteries indicated that the cold-induced adrenergic contraction was largely due to activation of the ␣ 2c subtype of adrenoceptors. 39 Notably, pharmacological and Western analysis revealed that the expression of ␣ 2c receptors was more prominent distally than proximally in the tail artery, mimicking the situation in humans, in whom the ␣ 2 response is greater in the more thermosensitive region of the upper extremity. In the murine arteries, the ␣ 2c adrenoceptors do not contribute to adrenergically evoked contraction at 37°C, but are responsible for the augmentation of adrenergic contraction with cooling. The contribution of postjunctional ␣ 2c adrenoceptors to cold-induced vasoconstriction is due to a rather quirky trait of these receptors. Flavahan and colleagues showed that with cooling, these receptors redistribute from the interior of the vascular smooth muscle cell to the membrane. 40 There they can be activated by norepinephrine to induce vasoconstriction. This cold-induced redistribution of receptors appears to be under the control of Rho kinase, a small GTP-binding protein known to be involved in cell motility and contraction.
The 'local fault' revealed?
In view of the evidence discussed above, an obvious question is whether Raynaud's disease is due to an increase in the expression or activity of these postjunctional ␣ 2 adrenoceptors. Certainly, the evidence indicates that these receptors are present in human skin vessels. Furthermore, the cutaneous vasoconstriction mediated by these receptors seems to be augmented by cold. Additional evidence indicates that the expression and/or activity of these receptors are increased in patients with Raynaud's disease. Keenan and Porter observed an increased expression of ␣ 2 adrenoceptors on platelets from Raynaud's patients in radio-ligand-binding studies. 41 This is consistent with the observation that in comparison to normal subjects, Raynaud's patients exhibit a greater vasoconstriction to serotonin and ␣ 2 receptor agonists, whereas the response to an ␣ 1 agonist is not different. 42 Of greater significance, Freedman and coworkers found that intra-arterial yohimbine, the ␣ 2 antagonist, but not prazosin, the ␣ 1 antagonist, prevented digital vasospasm in patients with Raynaud's disease. 43 Interestingly, the postjunctional ␣ 2 adrenoceptors may also contribute to Raynaud's phenomenon in patients with scleroderma. Thus, cutaneous arterioles isolated from these individuals and studied in a myograph manifest normal endothelial and vascular smooth muscle responses, and even contracted normally to ␣ 1 adrenoceptor agonists. By contrast, the contraction evoked by ␣ 2 adrenoceptor agonists was markedly enhanced. 44 Thus, the evidence favors a major involvement of ␣ 2 adrenoceptors as a mechanism underlying cold-induced vasospasm in Raynaud's disease. However, it is clear that other factors also contribute to cold-induced vasoconstriction. Thus, in normal individuals and in Raynaud's patients, adrenergic receptor antagonists blunted, but did not abolish, cutaneous vasoconstriction evoked by cooling of the digit. 27 A non-adrenergic mechanism for cold-induced vasoconstriction has also been demonstrated in the central ear artery of the rabbit, 45 which plays a major role in thermoregulation. In this vessel, cold-induced contraction was not blocked by antagonists of the adrenergic, serotonergic or purinergic receptors. The remaining contraction appeared to be due to calcium-induced calcium release as it was blocked by antagonists of calcium entry or intracellular calcium release. Mechanisms that might contribute to this locally induced vasoconstriction are considered further below.
Involvement of ␣ 2 adrenoceptors in the cold-induced vasospasm of Raynaud's disease would help to explain why the disorder is difficult to treat. Calcium channel blockers can increase digital blood flow, but they have limited utility to reduce vasospastic episodes in Raynaud's disease because of attendant hypotension. This is probably because calcium channels are widely distributed in the vasculature, and play an important role in controlling systemic vascular resistance via postjunctional ␣ 1 adrenoceptors as well as by ␣ 2 adrenoceptors and other vasoconstrictor mediators. Probably for similar reasons, oral ␣-adrenergic antagonists, including the ␣ 1 receptor antagonists (e.g. prazosin), also provide suboptimal results: they often cause orthostatic hypotension and tachycardia. Indeed, since postjunctional ␣ 2 adrenoceptors have a more restricted distribution, as discussed above, it seems likely that an antagonist of the ␣ 2 receptor, preferential to the ␣ 2c subtype, and hydrophilic (so as to limit entry through the blood-brain barrier), might be a 'silver bullet' for Raynaud's disease, preferentially limiting cold-induced vasospasm in the digital circulation, without reducing systemic vascular resistance. By contrast, there is early evidence that a specific ␣ 2 adrenoceptor antagonist may be useful. In patients with Raynaud's phenomenon secondary to scleroderma, the time for rewarming after a cold stimulus was reduced in patients treated with the ␣ 2c receptor antagonist OPC-28326, suggesting that selective ␣ 2c -adrenergic blockade improves digital skin perfusion. 46 Unfortunately, this agent is not yet approved in the treatment of Raynaud's disease. The only available oral ␣ 2 adrenoceptor antagonist in the USA and Europe is yohimbine. Yohimbine is not specific for postjunctional ␣ 2 receptors. Because it crosses the blood-brain barrier, it can increase sympathetic outflow by central neural effects, and/or by antagonizing the peripheral pre-junctional ␣ 2 adrenoceptors.
A surgical approach to ablation of adrenergic influence has been utilized for severe cases of Raynaud's phenomenon. Most usually, these are patients with secondary Raynaud's phenomenon with tissue loss. In such patients, microsurgical arteriolysis (resection of fibrotic adventitia with digital sympathectomy) has been reported to heal digital ulcers and improve digital ischemic pain. 47 This procedure is not indicated for primary Raynaud's disease.
Thus, the evidence discussed above provides a strong case for postjunctional ␣ 2 adrenoceptors, with their localized distribution and particular characteristics playing an important role in cold-induced vasospasm in Raynaud's disease. However, this evidence does not entirely account for cutaneous vasospasm in Raynaud's disease.
A central neural abnormality in Raynaud's disease
Investigations into the cardiovascular responses evoked by stressors in patients with Raynaud's disease has demonstrated that these patients manifest an impaired ability to habituate upon repetition of the stressful stimulus. This implies alteration in the central neural control of the cardiovascular system, specifically in the pathways that modulate the alerting or defense response. This is a very well-known pattern of response that is characteristically evoked by novel or noxious stimuli. 48 These include the sight, sound or touch of something unexpected or painful. In human subjects, they include mental arithmetic performed under duress, a sudden sound or the cold pressor test. The pattern of the alerting response includes tachycardia, vasoconstriction in cutaneous, mesenteric and renal circulations, but vasodilation in skeletal muscle. It also includes other autonomically mediated responses such as pupillary dilation, sweating and piloerection. The magnitude of the individual components of the response are graded with the strength of the stimulus and may range from trivial to dramatic. But, the over-arching characteristic of the alerting or defense response is that it generally shows habituation on repetition of the stimulus. A minority of subjects show sensitization, such that the response persists or becomes larger upon repetition of the stimulus (see 49 ).
The effect of repetition of stimuli was studied in patients with Raynaud's disease and in sex-and agematched control subjects. 50 A pure sound delivered by headphones was used as the stressor and was delivered five times at randomized intervals on day 1 and again on days 3 and 5, to test for short-and medium-term habituation. For each sound, the subjects were asked to score their level of discomfort on a rising scale of 0-10.
In response to the first sound, both groups showed the pattern of the alerting response, including vasodilation in forearm muscle and vasoconstriction in the finger. The magnitude of the finger vasoconstriction was similar in the two groups. Upon repetition of the sound on day 1, the evoked pattern of response showed no obvious change in either group. However, on each of days 3 and 5, the control subjects showed habituation such that the individual components of the alerting response decreased from the first to the fifth stimulus. They also showed habituation over the three sessions such that the tachycardia, finger vasoconstriction and the forearm vasodilation had virtually disappeared by day 5 (Figure 2) . Thus, the control subjects showed short-and medium-term habituation. By contrast, the primary Raynaud's patients showed no habituation at all. The finger vasoconstriction and forearm vasodilation evoked by the last sound on day 3 were comparable in magnitude with those evoked by the first sound on day 1. By contrast, the two groups awarded very similar scores to the level of discomfort produced by the first sound on day 1, and both groups showed habituation of their perception of discomfort over the three experimental sessions. 50 Thus, when using sudden sound as the stimulus, primary Raynaud's patients were no more easily stressed than control subjects in terms of their perception of the stressor nor in terms of their initial cardiovascular response to it. However, whereas their perception of the stressor habituated in the normal way, the primary Raynaud's patients showed impaired habituation of the cardiovascular components of the alerting response. The cutaneous vasoconstriction is due to an increase in sympathetic noradrenergic nerve activity, whereas the vasodilation in forearm muscle is caused by the combined effect of a decrease in sympathetic noradrenergic activity, the action of epinephrine on ␤ adrenoceptors and possibly by an increase in the activity of sympathetic dilator fibers. Thus, the most straightforward interpretation of these results is that primary Raynaud's patients show impairment of the central neural process of habituation 49 rather than a simple hyper-reactivity of the sympathetic nervous system as originally proposed by Raynaud (see 47 ).
In a subsequent study, mild cooling was used as the stimulus and yielded very similar results. One hand was transferred from water at thermoneutral temperature to cool water at 16 o C for 5 min, but in other respects the protocol was the same as that used for the sound stimulus. 50 The peak magnitude of the finger vasconstriction was no greater in the primary Raynaud's patients on day 1, even though they gave the cool water a higher score for level of discomfort. The control subjects showed habituation of the pattern of alerting response even within day 1, but the primary Raynaud's patients showed no habituation at any part of the alerting response within the sessions or over the three sessions. 50 Although the results of both studies are consistent with impairment of the central neural process of habituation in Raynaud's disease, an alternative explanation was possible. Namely, that those individuals with Raynaud's disease do show central neurally mediated habituation of cutaneous vasoconstriction but, on repetition of the stimulus, they also show a counteracting and gradual increase in the size of the cutaneous vasoconstriction. This is due to facilitatory effects occurring at the level of the sympathetic neurons in the spinal cord, or at the neuro-effector junction of the sympathetic fibers and cutaneous blood vessels.
Thus, the same protocol was used, but the stimulus was venous stasis of one arm, produced by inflating a cuff on the upper arm to 40 mmHg for 2 min. 51 The rationale for this was that venous stasis causes sympathetically evoked vasoconstriction in cutaneous circulation, which is mediated by a local venoarteriolar reflex that does not require transmission through the spinal cord. 52 In the primary Raynaud's patients and controls, the first venous stasis evoked finger vasoconstriction comparable in magnitude to that evoked by the first sound and first cool stimulus. This response showed no habituation in either group, within, or over the three experimental sessions. 51 Taken together, these results suggest that patients with Raynaud's disease have impaired habituation of the whole cardiovascular pattern of response evoked by stressful stimuli, including mild coldness. Interestingly, an apparently similar impairment of habituation of this alerting response occurs in patients with essential hypertension. 53 For those individuals with Raynaud's disease, their lack of habituation suggests that they must repeatedly undergo cutaneous vasoconstrictor responses to the many novel, stressful and unpleasant stimuli we all experience in everyday life, whereas in normal subjects such responses are dampened by the process of habituation. Repeated vasoconstriction seems very likely to contribute to the development of vasospasm, particularly if combined with abnormalities in the local control of finger blood vessels, as discussed above and below.
Non-adrenergic mechanisms
It is clear from the findings discussed above that factors other than adrenergic mechanisms are likely to contribute to the vasospasm of Raynaud's disease.
5-Hydroxytryptamine (5-HT serotonin)
In one study, finger blood flow in primary Raynaud's patients was reduced to zero by severe cooling. Administration of ketanserin, a 5-HT 2A receptor antagonist, accelerated restoration of finger blood flow after removal of the cold stimulus, suggesting that 5-HT contributes to vasospasm. 54 Furthermore, in one study, levels of 5-HT in plasma and in platelets were elevated in primary Raynaud's patients. 55 However, a later study showed that plasma levels of 5-HT were no higher in primary Raynaud's patients than controls and cooling did not change the arteriovenous difference for 5-HT across the forearm in either primary Raynaud's patients or controls. Further, in three primary Raynaud's patients, there was no release of 5-HT into the venous efflux during a period of vasospasm. Thus, involvement of peripherally released 5-HT in augmenting vasoconstriction is not conclusive. 56 On the other hand, a selective serotonin re-uptake inhibitor (SSRI), fluoxetine, was shown to reduce the frequency and severity of vasospastic episodes in patients with Raynaud's disease, and to increase the rate of rewarming after a cold challenge. 57 It seems most likely that this agent achieved its beneficial effects by acting within the central nervous system since inhibition of re-uptake would be expected to increase the plasma concentration of 5-HT. This is important in view of the evidence that the central neural processing involved in habituation of the cardiovascular components of the alerting response to acute stressors is impaired in Raynaud's disease (see above), and given that SSRIs are anxiolytic agents.
Endothelin
In the studies discussed above involving repetition of a mild, cool stimulus, the magnitude of the finger vasoconstriction measured at peak in response to the first stimulus was the same in patients with Raynaud's disease and in controls. 50 However, the finger vasoconstriction was longer-lasting in the primary Raynaud's patients than in controls, and it became more prolonged when the stimulus was repeated. Further, blood sampled from the venous drainage of the cooled hand in the Raynaud's subjects showed a 30% increase in the concentration of endothelin-1 (ET-1), whereas that of the control subjects showed no change (Figure 3 ). 50 This finding is of particular interest because ET-1 is a potent vasoconstrictor with a sustained effect. 58 ET-1 is released from the endothelium during vasoconstrictor responses evoked by norepinephrine and during local hypoxia. This raises the possibility that ET-1 prolongs reflex finger vasoconstrictor responses in patients with primary Raynaud's disease. 59, 60 This proposal accords with previous evidence that the plasma level of ET-1 are elevated under basal conditions in patients with Raynaud's disease. Further, in the patients only, modest cooling of the hand to ~18 o C increases ET-1 in the venous efflux of the forearm, whereas cooling the hand to 13 o C increases ET-1 efflux in the controls as well as the patients. 59 This, in turn, agrees with the finding that in control subjects the severe cooling of the cold pressor test caused an increase in the efflux of ET-1. 60 By contrast, it has been reported that ET-1 was not released, even during severe cooling that induced vasospasm in primary Raynaud's patients and intense constriction in controls. 61 However, in this study, only one finger was cooled, and the venous sample was taken from the antecubital fossa, 61 possibly limiting the ability to detect a signal.
ET-1 is cleaved from Big ET by its converting enzyme and this process is inhibited by nitric oxide (NO). ET-1 produces vasoconstriction by acting mainly on receptors of the ET A subtype on the vascular smooth muscle. However, it also acts on ET B receptors on the endothelium to increase the synthesis of NO. 62 Thus, the release of ET-1 and its vasoconstrictor action might well be accentuated in primary Raynaud's patients if their endothelial function is disturbed.
Endothelium-dependent dilation
The endothelium can release a panoply of vasodilator factors, including NO; vasodilator prostaglandins (PGs), of which the most important is prostacyclin (PGI 2 ); endothelium-derived hyperpolarizing factor (EDHF); adenomedullin; atrial natriuretic peptide; and carbon monoxide. A deficiency of one or more of these dilator factors could potentially increase the responsiveness of digital arteries to vasoconstrictor influences and therefore increase the likelihood of vasospasm. 
Nitric oxide
In secondary Raynaud's phenomenon, in which there are structural alterations in the vessel walls, it might be expected that endothelial function is impaired. 3 Indeed, in scleroderma, microvascular endothelial cells taken from the dermis show a reduction in mRNA for NO synthase (NOS), a reduction in NOS protein and a consequent reduction in NO synthesis. 63 No similar studies have been performed on the endothelium of patients with primary Raynaud's disease. However, it was reported that the dilator response induced in the finger by iontophoresis of the NO donor, sodium nitroprusside, was depressed in primary Raynaud's patients relative to controls. 64, 65 Further, in one of these studies, the finger dilation induced by iontophoresis of the endotheliumdependent dilator acetylcholine (ACh), was also depressed in the primary Raynaud's patients relative to controls, but it was not enhanced by chronic administration of L-arginine, the substrate of NOS. 66 Thus, it seems that the dilator action of NO is depressed in Raynaud's disease, but that NO synthesis is not substrate-limited. It is not clear whether NO synthesis is otherwise depressed.
Oxidative stress
The bioavailability of NO can be depressed by oxidative stress. Oxygen-derived free radicals can rapidly oxidize NO, thereby limiting NO-induced dilation. The product of NO and the superoxide anion is peroxynitrite, a highly reactive free radical that may disrupt vascular signaling. 67 The fact that oxidative stress has been implicated in several vascular pathologies, including atherosclerosis and restenosis, 68 and ischemia-reperfusion damage, 69 raises an obvious question as to whether it is also involved in Raynaud's disease. This has been put to the test in one clinical trial in which it was found that probucol, a lipidlowering agent with antioxidant properties, was superior to the calcium channel blocker nifedipine in reducing the incidence of vasospasms in Raynaud's disease. 70 This observation is consistent with a role for oxidative stress in the pathophysiology of Raynaud's disease and may open a new therapeutic avenue. It would not be surprising if oxidative stress occurs in Raynaud's disease as a consequence of repeated episodes of ischemia-reperfusion associated with vasospastic attacks.
Endothelium-dependent constriction
If the dilator action of NO is limited in Raynaud's disease, it would be expected that dilator responses evoked in the finger by ACh would also be depressed, for this response has been partly attributed to NO in normal subjects. 71 The literature is confusing on this point. Thus, as indicated above, the digital vasodilator response to ACh has been reported to be depressed, 66 but in other studies it was found to be comparable 64 or even enhanced 72 in primary Raynaud's patients. However, the results of a recent study suggest that these disparities may be explained by the fact that in previous studies the primary Raynaud's patients and controls were not well matched for age, sex and preor post-menopausal status. 73 When subjects were matched according to age and pre-or post-menopausal status, then the AChinduced responses were fully comparable in the preand post-menopausal primary Raynaud's patients and pre-menopausal controls, but depressed in the postmenopausal control women. 73 That the digital dilator responses were depressed in post-menopausal relative to pre-menopausal control women, is consistent with previous findings that endothelium-dependent vasodilation is impaired after menopause. 74 It is an intriguing but unexplained observation that endothelium-dependent vasodilation was preserved after menopause in the Raynaud's patients. Given that ACh-induced dilator responses were at least as large in primary Raynaud's patients as controls, and in view of the evidence that the dilator action of NO is limited in Raynaud's disease (see above), it may be that other endothelial vasodilator factors (e.g. PGI 2 and/or EDHF) are increased in a compensatory fashion in Raynaud's disease.
Vasoconstrictor COX products
The possible role of vasoconstrictor prostanoids in Raynaud's disease was tested in the study mentioned above 73 by oral administration of aspirin to inhibit cyclo-oxygenase (COX) activity. Dilator responses evoked in the finger by iontophoresis of ACh were tested before and after aspirin. Aspirin had no effect on ACh-evoked responses in pre-menopausal control women, but enhanced the responses to ACh in postmenopausal control women. By contrast, aspirin enhanced the ACh-evoked responses in both pre-and post-menopausal women with Raynaud's disease. 73 These findings suggest that a vasoconstrictor product of COX limits finger vasodilation in post-menopausal control women and in pre-and post-menopausal women with Raynaud's disease.
The results obtained in the control women agree with the fact that COX inhibition had no effect on dilator responses evoked by ACh in the forearm of pre-menopausal control women, but enhanced those evoked in pre-menopausal control women who had been ovariectomized, an effect reversed by supplementary estrogen. 75 It may also be noted that in men Ͼ60 years, but not in younger men, COX inhibition enhanced forearm dilator responses evoked by ACh infusion, 76 and that even in young men aspirin enhanced dilator responses evoked in the finger by ACh. 77 Taken together, these observations suggest that when the influences of estrogen are removed or absent, the counteracting influences of vasoconstrictor COX products upon endothelium-dependent dilation become manifest. They also raise the possibility that the finger circulation is more susceptible than the forearm circulation to these vasoconstrictor products.
It may be that this deficit is related to the depressed or limited dilator action of NO in Raynaud's disease, as discussed above. Further, it could be that women with Raynaud's disease lack the normal facilitatory influence of estrogen on NO synthesis and action. 78 Another possibility is that the known facilitatory influence of estrogen on the COX pathway 79 is aberrant in Raynaud's disease, such that the production of vasoconstrictor rather than vasodilator COX products is favored.
The nature of the vasoconstrictor COX products
The COX pathway in endothelial cells can produce several different substances that are vasoconstrictor or have vasoconstrictor consequences. These include vasoconstrictor PGs, thromboxane (TXA 2 ), PGH 2 (prostaglandin H 2 ) the endoperoxide intermediate, and superoxide anions (O 2 Ϫ ). Superoxide anions can stimulate PGH 2 and TXA 2 production by vascular smooth muscle 80, 81 as well as limit the dilator action of NO (see above).
There is scant information on the functional role of these various products in situations relevant to vasospasm. However, in recent experiments on young control men, it was shown that the antioxidant vitamin C produced a potentiating effect similar to aspirin on digital vasodilation induced by ACh. 77 Since O 2 Ϫ anions can be generated by the COX pathway (see above), a possibility raised is that the beneficial effect of probucol on the incidence of vasospastic attacks in Raynaud's disease (see above) is attributable, at least in part, to the scavenging of O 2 Ϫ anions produced by the COX pathway.
Further, the potentiating effect of estrogen on contraction evoked in rat aorta by ␣ 1 agonists that was mentioned above, was ascribed to a vasoconstrictor COX product that was TXA 2 and/or PGH 2 . 19 Thus, the possibility is raised that estrogen-induced release of TXA 2 and/or PGH 2 not only limits endotheliumdependent dilation, but augments the ␣ 1 adrenoceptor component of digital vasoconstriction evoked by sympathetic activation in Raynaud's disease. This could explain why Raynaud's disease is more common in women than men, why the severity of the disease is greater between menarche and menopause, 9 and why unopposed estrogen therapy in post-menopausal women is positively associated with the disease. 82 Consistent with the proposal that a vasoconstrictor COX product accentuates vasoconstriction in Raynaud's disease, is the finding that the TXA 2 synthesis inhibitor dazoxiben shortened the duration of vasospasm evoked by cooling in patients with Raynaud's disease. By contrast, in a subsequent clinical trial performed with dazoxiben, there was no reduction in the number of vasospasm episodes 83 and a similar finding was made in a different trial when a specific TXA 2 receptor antagonist was used. 84 The results of these clinical trials do not necessarily overturn the proposal, simply because TXA 2 may not be the only COX product that contributes to the vasospasm and because factors other than COX products may also be involved.
Calcitonin gene-related peptide (CGRP)
Another line of research that has been followed in the attempt to understand the pathogenesis of Raynaud's disease is the idea that the influence of sensory nerve activation on digital vasculature is impaired. Normal digital skin is richly innervated by CGRP-containing nerves that play a role in nociception, 85 but the density of this innervation is much sparser in patients with Raynaud's disease. 86 Bunker et al have argued that, in normal subjects, the CGRP-containing digital cutaneous nerves are stimulated in response to cold and release CGRP which produces dilation, and helps to counteract cold-induced vasoconstriction. 87 Thus, they maintain that CGRP is a major contributor to cold-induced vasodilation. They further propose that ET-1, which others have shown is found released in response to cooling (see above), not only produces local constriction, but activates the CGRP-containing sensory nerves to produce vasodilation. In patients with Raynaud's disease, the deficiency of CGRPcontaining nerves may limit the manifestation of cold vasodilation and allow an unopposed vasoconstrictor effect of ET-1.
This novel hypothesis is consistent with the results of a series of experimental studies. In normal subjects an, intradermal injection of ET-1 evoked local vasoconstriction surrounded by an area of vasodilatationa prolonged erythematous response. The erythematous response was attenuated by local application of capsaicin or local anesthetic, implicating peptidergic sensory nerves, while intradermal injection of CGRP also produced a vasodilation. 88 When similar experiments were repeated in control subjects and primary Raynaud's patients with the hand maintained at a temperature of either 20 o C or 5 o C, the lower temperature produced basal vasodilation in the controls, but not in the primary Raynaud's patients. The vasoconstrictor response to intradermal injection of ET-1 was greater in the primary Raynaud's patients, particularly at 5 o C. Moreover, the erythematous response to ET-1 was substantially smaller in the primary Raynaud's patients, particularly at 5 o C. These results are therefore consistent with a reduced release of CGRP from sensory nerves in response to cold per se, or to ET-1 released by cooling in primary Raynaud's patients, while a smaller response to injected, exogenous CGRP in the cold might be explained by a smaller facilitatory effect of endogenously released CGRP, or by a greater counteracting constrictor effect of endogenously released ET-1.
Although these results are consistent with the general hypothesis put forward by Bunker et al, 87 they are not conclusive. A study with a selective CGRP receptor antagonist is required to show the extent to which CGRP is essential to, or contributes to, cold-induced cutaneous dilation in control subjects and to see whether it is this effect of CGRP that is deficient in primary Raynaud's patients. The role of the endothelium in cold-induced dilation also needs examination. Although CGRP receptors are present on endothelial and vascular smooth muscle cells, it seems that in skin, CGRP-induced dilation is largely independent of NO synthesis. 89, 90 However, the vasoconstrictor effect of ET-1 is known to be limited by its dilator action exerted via ET B receptors on endothelium. 91 Thus, it needs to be established whether the depressed erythematous response to ET-1 and the depressed dilator response to cold per se reported in primary Raynaud's patients, reflects an impaired dilator influence of NO rather than a deficit of CGRP-containing nerves. The question also arises as to whether the deficit of these nerves in Raynaud's disease is a primary condition or secondary to repeated vasospasm.
A genomic basis for Raynaud's disease?
The fact that there is clustering of Raynaud's disease in families 5, 9 raises the obvious question of whether the disease has a definable genetic basis. There is reputedly an increased concordance for Raynaud's disease in monozygotic versus dizygotic twins. 92 Moreover, in affected family members, whole genome linkage has implicated five regions of chromosomes with possible linkage. 93 The genes that map to these regions and that were considered as potential candidates for involvement in Raynaud's disease are those for the 5-HT 1B and 5-HT 1E receptors and for the ␤ subunit of the acetylcholine (ACh) receptor: nervereleased ACh has been implicated in cutaneous vasodilation in human skin. 71 Of course, these regions may contain other genes that are related to the pathophysiology of Raynaud's disease.
In another study, 5 the allele frequencies of known polymorphisms in four candidate genes that seemed likely to be involved in Raynaud's disease, were compared in a phenotypically homogenous group of patients with Raynaud's and a normal control population. The genes chosen for study were endothelial NO synthase (eNOS), ET-1 and the ET A receptor gene and the bradykinin (BK) receptor gene on the basis that there is impaired venodilation to BK in patients with Raynaud's disease. 94 No significant differences in allele frequencies were found between the primary Raynaud's patients and controls, suggesting that the common molecular variants of these candidate genes are not involved in the genesis of the disease. It is interesting that in this study, patients with primary Raynaud's reported a higher personal history of migraine than controls (33% vs 7%) and the prevalence of migraine was greater in the patients who had family members with the disease. This provides a firm basis for the idea that primary Raynaud's is part of a more widespread disorder of vascular tone that is likely to have a genetic basis, even if environmental factors are also involved in inducing vasospasm.
Summary: towards a unifying hypothesis
The original hypothesis that Raynaud's disease is solely due to hyper-reactivity of the sympathetic nervous system can be discounted. However, the sympathetic nervous system is certainly implicated in that the vasospastic attacks in the fingers that characterize Raynaud's disease are generally evoked by cold or emotion, both of which increase sympathetic nerve activity to the skin.
Raynaud's disease is far more common in women than men. Even in unaffected individuals, there is a gender difference in cutaneous blood flow. The reduced finger blood flow in pre-menopausal women appears to be due to the influence of estrogen upon sympathetic nerve activation. This effect of estrogen could be due to a tonic effect of the hormone on sympathetic nerve traffic, a direct effect on adrenergic signaling, and/or amplification of adrenergic response by vasoconstrictor prostanoids.
Vasoconstriction evoked by ␣ 2 adrenoceptors is strongly implicated in the response to cold. Cold augments vasoconstriction evoked by ␣ 2 receptor stimulation in arterial vessels of the finger. This effect may be due to the fact that ␣ 2 receptors redistribute to the surface of vascular smooth muscle cells in response to cold. It is therefore highly significant that post-synaptic ␣ 2 receptors make a larger contribution to resting vasoconstrictor tone in the fingers of patients with Raynaud's disease than controls. Moreover, acute blockade of ␣ 2 , but not ␣ 1 receptors has been shown to attenuate vasospasm evoked by cold in Raynaud's patients.
Patients with Raynaud's disease apparently belong to the minority of the population that shows impairment of central neural habituation of the pattern of cardiovascular response evoked by acute emotional stress. Thus, it can be inferred that throughout the working day, repeated vasoconstriction must occur in the fingers as part of the response to various stressors. This would surely facilitate the development of vasospasm in individuals who have additional characteristics implicated in Raynaud's disease.
ET-1, and possibly 5-HT, have been implicated in prolonging vasospasm. The action of 5-HT in vasospasm may be within the central nervous system rather than peripheral. Cooling releases ET-1 from vascular endothelium of the extremities, the release being particularly pronounced in patients with Raynaud's disease relative to controls. In addition, a deficit of CGRP containing sensory nerves in the fingers in Raynaud's disease may impair an important countervailing force against cold-induced vasoconstriction.
There is evidence that the dilator action of NO is depressed in the fingers of patients with Raynaud's disease. This may be attributed, at least in part, to inactivation of NO by oxidative stress resulting from repeated episodes of vasospasm and consequent ischemia-reperfusion. Reduced availability of NO would be expected to lead to impairment of the normal ability of NO to facilitate shear-stress or flow-induced vasodilation, and to limit ET-1 production. Further, vasoconstrictor responses evoked by, for example, ␣ 2 adrenoceptor stimulation and ET-1 may be enhanced, for these responses are normally limited by NO released by endothelial ␣ 2 and ET B receptor stimulation.
Endothelium-dependent dilation in the fingers is also limited in Raynaud's disease by the action of vasoconstrictor products of the COX pathway. This influence is present in both pre-and post-menopausal women with Raynaud's disease, but only in control women after the menopause. It seems that women with Raynaud's disease may lack an influence of estrogen that normally attenuates the synthesis or action of vasoconstrictor COX products. This may be linked to reduced availability of NO. The facilitory effect of estrogen on ␣ 1 adrenoceptor-mediated vasoconstriction has also been attributed to endothelium-derived vasoconstrictor COX products. A change in the balance from the production or action of vasodilator to vasoconstrictor COX products, would be expected to increase the likelihood of vasospasm.
It is becoming apparent that the cellular mechanisms that have been implicated in Raynaud's disease by experimental and clinical studies are, to an extent, interdependent. Thus, once the conditions are set for potentiation or prolongation of the vasoconstrictor response to cold or emotion, several of these mechanisms are likely to facilitate one another's effects. At this stage, it is impossible to identify an initiating trigger or triggers for the genesis of Raynaud's disease. Indeed, it seems likely that several characteristics must occur together to induce the disease. Familial clustering of individuals with the disease and studies indicating five particular regions of chromosomes with linkage among affected family members suggest a genetic basis to Raynaud's disease: candidate genes that map to these regions include those for two 5-HT receptor subtypes. On the other hand, another genetic study showed that particular polymorphisms of the genes for eNOS, ET-1 and the ET A receptor seem unlikely to be involved in the genesis of the disease. It may be that variants of genes that modulate the functioning of ␣ 2 adrenoceptors, the central neural process of habituation, and/or the influence of estrogen on endothelial biosynthetic pathways provide the essential triggers for Raynaud's disease. Once initiated, environmental factors may maintain the disease. These mechanistic insights into Raynaud's disease may lead to more effective therapies in the future.
